Two psychedelic companies will study the effects of natural psilocybin and MDMA in healthy volunteers – Optimi Health (OTC:OPTHF)

Health Canada regularly receives requests for clinical trials. This time the licensed producer of EU-GMP natural psilocybin and MDMA Optimi Health Corp. OPTHF together with ATMA Travel Centers say they intend to submit a Phase I Clinical Trial Application (CTA) to document Optimi’s security natural psilocybin biomass and MDMA in healthy patients.

The study plans to evaluate both safety -blood pressure, temperature, heart rate, ECG readings- and additional markers -i.e. a mystical experience questionnaire- in healthy subjects after the intake of the company’s proprietary formulation of natural psilocybin and MDMA.

Bill Ciprick, CEO of Optimi expressed his ardor to begin this trial: “To the thousands of trained professionals who are waiting to experience Natural Psilocybin and MDMA, EU-GMP, we share their excitement and believe we have a ethical responsibility to provide their with a life-changing product that receives a massive number the attention of regulators around the world.

Behalf ATMA, CEO David Harder recognized the importance of CTA context and affirmed the company’s commitment to building a therapist-centered and therapist-directed support and training approach.

Harder believes that clinical evidence through Experimental learning on the effect of these molecules “is essential to provide a solid training program for therapists to prepare for the need that is already at our doorstep.

The current partnership aims to expand the relationship between the two companies, which began with a psilocybin supply agreement earlier in 2022. In it, Optimi will be the official clinical trial sponsor while ATMA will deliver clinical research expertise through its medical advisory team.

Photo courtesy of Pexels.

About Robert Wright

Check Also

The FAA has asked for comment on the small airplane seats. Will they grow?

Comment this story Comment ” Cramped “. “Unsafe.” “Torture.” Many of the more than 26,000 …